BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30557309)

  • 1. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
    de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
    PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis.
    Hertel JD; Huettner PC; Pfeifer JD
    Int J Gynecol Pathol; 2014 Mar; 33(2):127-34. PubMed ID: 24487466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis.
    Dogan Altunpulluk M; Kir G; Topal CS; Cetiner H; Gocmen A
    J Obstet Gynaecol; 2015 May; 35(4):397-402. PubMed ID: 25279582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion.
    Santoro A; Angelico G; Inzani F; Spadola S; Arciuolo D; Valente M; Musarra T; Capelli G; Fanfani F; Gallotta V; Scambia G; Zannoni GF
    Eur J Surg Oncol; 2021 Feb; 47(2):338-345. PubMed ID: 32788094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
    Pasanen A; Loukovaara M; Tuomi T; Bützow R
    Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
    Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
    de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
    Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.
    Pelletier MP; Trinh VQ; Stephenson P; Mes-Masson AM; Samouelian V; Provencher DM; Rahimi K
    Hum Pathol; 2017 Apr; 62():33-39. PubMed ID: 27864117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microcystic, elongated and fragmented invasion pattern in endometrial carcinoma: the clinicopathology analysis].
    Zhang XB; Zhao CL; Qi XL; Qin Y; Wang Y; Shen DH
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):811-815. PubMed ID: 30585018
    [No Abstract]   [Full Text] [Related]  

  • 13. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma.
    Han G; Lim D; Leitao MM; Abu-Rustum NR; Soslow RA
    Histopathology; 2014 Feb; 64(3):389-98. PubMed ID: 24215212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study.
    Stålberg K; Bjurberg M; Borgfeldt C; Carlson J; Dahm-Kähler P; Flöter-Rådestad A; Hellman K; Hjerpe E; Holmberg E; Kjølhede P; Marcickiewicz J; Rosenberg P; Tholander B; Åvall-Lundqvist E; Högberg T
    Acta Oncol; 2019 Nov; 58(11):1628-1633. PubMed ID: 31373248
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
    Lax SF; Tamussino KF; Lang PF
    Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
    Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower uterine segment involvement in lymphovascular space invasion and lymph node metastasis in endometrioid endometrial cancer.
    Cokmez H; Yilmaz A
    Ginekol Pol; 2019; 90(6):314-319. PubMed ID: 31276182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
    Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
    Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.